Search Result

Results for "

GPIIb-IIIa antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (13) Isotope-Labeled Compounds (2) P-glycoprotein (1) P-selectin (1) P2Y Receptor (3) Protease Activated Receptor (PAR) (1)
By Research Areas:	Cardiovascular Disease (16) Inflammation/Immunology (3) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10304A

Orbofiban acetate	Integrin	Cardiovascular Disease
Orbofiban acetate is an orally active platelet *GPIIb/IIIa* antagonist that inhibits platelet aggregation.

HY-125373

L-767685	Integrin	Cardiovascular Disease
L-767685, the ethyl ester prodrug of L-767679 (HY-116925), is a non-peptide glycoprotein IIb/IIIa receptor (GPIIb-IIIa receptor) antagonist. L-767679 has a potent anti-platelet aggregation effect. L-767685 can be used for research on antithrombosis .

HY-10304

Orbofiban	Integrin	Cardiovascular Disease
Orbofiban is an orally active platelet *GPIIb/IIIa* antagonist that inhibits platelet aggregation.

HY-117177

XV459	Integrin	Cardiovascular Disease
XV459 is an orally active platelet *GPIIb/IIIa* receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research .

HY-10306

Gantofiban	Integrin	Cardiovascular Disease
Gantofiban is a *GPIIb/IIIa* integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect .

HY-169827

EMD-132338	Integrin	Cardiovascular Disease
EMD-132338 is a *GPIIb/IIIa* (α_IIbβ₃) antagonist that inhibits platelet aggregation. EMD-132338 can be utilized in antithrombosis research .

HY-122230

UR-3216	Integrin	Cardiovascular Disease
UR-3216 is a selective, and orally active *platelet surface glycoprotein (GPIIb/IIIa) receptor* antagonist. UR-3216 has the potential for cardiovascular diseases research .

HY-P0038

MK-852 L-367073	Integrin	Cardiovascular Disease
MK-852 is an effective *GPIIb/IIIa* receptor antagonist. MK-852 can significantly inhibit the binding of fibrinogen to platelets in vitro. MK-852can be used for the study of thrombosis .

HY-10315

Elarofiban RWJ-53308	Integrin	Cardiovascular Disease
Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor α_IIbβ₃ (GPIIb/IIIa), with an IC₅₀ of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research .

HY-167848

DMP-728 free base XL-118	Others	Cardiovascular Disease
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC₅₀ of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .

HY-120080

UR-2922	Integrin	Others
UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.

HY-19248

ME-3277	Integrin	Cardiovascular Disease Neurological Disease
ME-3277 is a potent *GPIIb/IIIa* antagonist. ME-3277 reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery (MCA). ME-3277 can be used for the acute cerebral infarction research .

HY-10315A

Elarofiban diTFA	Integrin	Cardiovascular Disease
Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor α_IIbβ₃ (GPIIb/IIIa), with an IC₅₀ of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research .

HY-167686

Variabilin Homopisatin	Integrin	Cardiovascular Disease
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

HY-107867

(±)-Clopidogrel bisulfate	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate	Isotope-Labeled Compounds P2Y Receptor	Inflammation/Immunology
(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-106394

TP-9201	P-glycoprotein	Cardiovascular Disease
TP-9201 is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. TP-9201 inhibits the interaction between GPIIb/IIIa and fibrinogen, thereby suppressing platelet aggregation. TP-9201 exhibits similar inhibitory activity on adenosine diphosphate (ADP) (HY-W010918)-induced platelet aggregation in humans, baboons, and dogs (IC₅₀ = 1-3 μM), while showing lower activity in rabbits (IC₅₀ = 45 μM) and rats (IC₅₀ = 20 μM). TP-9201can be used in studies related to the prevention of rethrombosis after arterial thrombolysis .

HY-119158

VU0652925	Protease Activated Receptor (PAR) P-selectin	Inflammation/Immunology
VU0652925, an analog of BMS986120, is a PAR4 antagonist, with IC₅₀ values of 43 pM and 39.2 pM for PAC1 and P-selectin, respectively. VU0652925 is able to suppress GPIIbIIIa activation .

Cat. No.	Product Name	Target	Research Area

HY-P0038

MK-852 L-367073	Integrin	Cardiovascular Disease
MK-852 is an effective *GPIIb/IIIa* receptor antagonist. MK-852 can significantly inhibit the binding of fibrinogen to platelets in vitro. MK-852can be used for the study of thrombosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-167686

Variabilin Homopisatin	Natural Products Source classification Plants Dalbergia variabilis Fabaceae	Integrin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

Cat. No.	Product Name	Chemical Structure

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate
(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

(Rac)-Clopidogrel hydrogen-d9 sulfate

(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate
Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

Clopidogrel-13C,d3 sulfate

Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks